A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer

  • STATUS
    Recruiting
  • End date
    Dec 7, 2025
  • participants needed
    400
  • sponsor
    Centre Hospitalier Universitaire Dijon
Updated on 7 November 2021

Summary

The aim of BEVAMAINT is to improve benefic effect of maintenance therapy after a first line of induction chemotherapy for patients with colorectal cancer

Details
Condition Metastatic Colorectal Cancer
Treatment bevacizumab, Fluoropyrimidine
Clinical Study IdentifierNCT04188145
SponsorCentre Hospitalier Universitaire Dijon
Last Modified on7 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically confirmed metastatic colorectal adenocarcinoma before induction treatment
Measurable or non-measurable lesion before the induction treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Metastatic, unresectable disease according local practice after induction treatment
ECOG performance status 2
Disease control (complete response, partial response or stable disease) after 4-6 months of frontline induction chemotherapy with doublet (fluoropyrimidine + irinotecan or oxaliplatin) or triplet (fluoropyrimidine + irinotecan + oxaliplatin) +/- (cetuximab, panitumumab, bevacizumab) or IAH chemotherapy
Life expectancy > 3 months
Age 18 years
Patient is at least 4 weeks from any major surgery
Total bilirubin < 25 mol/L, ASAT < 3 x ULN, ALAT < 3 x ULN (ASAT , ALAT < 5 x ULN in case of hepatic metastasis) , PT >60% , PAL<2.5 x ULN ( < 5 x ULN in case of hepatic metastasis) - Neutrophils > 1500/mm3, platelets > 100 000/mm3, haemoglobin 9 g/dL
Creatinin clearance > 30 ml/min (MDRD) - if creatinin clearance comprised between 30 and 50 ml/min, see smPCs for dose adjustments
Proteinuria 2+ (dipstick urinalysis) (if more than 2+, so proteinuria at or 1g/24hour must be 1g)
Patient is able to understand, sign, and date the written informed consent
Evidence of post-menopausal status or negative urinary or serum pregnancy test for premenopausal female patients
Male and female patients of childbearing potential agree to use a highly effective contraceptive measure
Patient affiliated to a social security system

Exclusion Criteria

Myocardial infarction, severe coronaropathy or severe cardiac dysfunction less than 6 months prior randomization
Follow-up impossible
Patients with all metastases resected (R0/R1) after induction chemotherapy
Patient with a hand-foot syndrome > 1 before maintenance treatment
Known brain or leptomeningeal metastases
Other concomitant or previous malignancy, except: adequately treated in situ carcinoma in complete remission for > 5 years
Uncontrolled hypertension (defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy
Pregnancy or breast feeding
Treatment with sorivudine or analogs (brivudine)
Treatment with phenytoin or analogs
Partial or complete DPD deficiency (Uracilemia 16 ng/ml)
Peptic ulcer not healed after treatment
Any contraindication to bevacizumab or fluoropyrimidine treatments according to the updated SmPC
Intestinal perforation or intestinal fistula
Previous or active gastrointestinal bleeding
Thromboembolic event and/or history of thromboembolic event
Severe hepatic insufficiency
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note